Focused On-demand Library for Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q14191

UPID:

WRN_HUMAN

Alternative names:

DNA helicase, RecQ-like type 3; RecQ protein-like 2; Werner syndrome protein

Alternative UPACC:

Q14191; A1KYY9

Background:

The Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN, also known as Werner syndrome protein, plays a crucial role in maintaining genomic integrity. It exhibits both magnesium and ATP-dependent DNA-helicase activity and 3'->5' exonuclease activity, targeting double-stranded DNA with a 5'-overhang. This protein is pivotal in the dissociation of joint DNA molecules, aiding in homologous recombination, stalled replication forks, and DNA repair processes.

Therapeutic significance:

WRN's involvement in Werner syndrome and Colorectal cancer highlights its therapeutic significance. Werner syndrome, a progeroid syndrome, and Colorectal cancer, a common malignancy, are linked to variants affecting the WRN gene. Understanding WRN's role could lead to novel therapeutic strategies for these conditions.